1. Karayiannis P. Hepatitis B virus: old, new and future approaches to antiviral treatment. J Antimicrob Chemother. 2003; 51:761–785.
Article
2. Lau DT, Khokhar MF, Doo E, et al. Longterm therapy of chronic hepatitis B with lamivudine. Hepatology. 2003; 32:828–834.
Article
3. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348:808–816.
4. Yotsuyanagi H, Koike K. Drug resistance in antiviral treatment for infections with hepatitis B and C viruses. J Gastroenterol. 2007; 42:329–335.
Article
5. Tim S, Scott B, Stetphen L. Rescue therapy for drug resistant hepatitis B: another argument for combination chemo-atherapy? Gastroenterology. 2004; 126:343–350.
6. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48weeks of adefovir dipivoxil monotherapy. Hepatology. 2006; 43:1385–1391.
7. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006; 55:1488–1495.
Article
8. van Bömmel F, Zöllner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology. 2006; 44:318–324.
Article
9. Villet S, Pichoud C, Villeneuve JP, Trepo C, Zoulim F. Selection of a multipe drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology. 2006; 131:1253–1261.
10. Ratziu V, Thibault V, Benhamou Y, Polynard T. Successful rescue therapy with tenofovir in a patient with hepatic de-compensation and adefovir resistant HBV mutant. Comp Hepatol. 2006; 5:1.
Article
11. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45:507–539.
Article
12. Sasadeusz JJ, Locarnini SL, Macdonald G. Why do we not yet have combination chemotherapy for chronic hepatitis B? Med J Aust. 2007; 186:204–206.
Article
13. Marceliin P, Asselah T. Resistance to adefovir: a new chal-lenge in the treatment of chronic hepatitis B. J Hepatol. 2005; 43:920–923.
14. Mutimer D. Adefovir-lamivudine combination therapy and hepatitis B viral kinetics. J Hepatol. 2005; 43:200–202.
Article
15. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summury of a clinical research workshop. Hepatology. 2007; 45:1056–1075.
16. Aloman C, Wands JR. Resistance of HBV to Adefovir Dipivoxil: a case for combination antiviral therapy. Hepatology. 2003; 38:1584–1587.
Article
17. Augus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003; 125:292–297.
Article
18. Brunelle MN, Jacquard AC, Pichoud C, et al. Susceptibility to antivirals of a human HBV strain with mutations confer-ring resistance to both lamivudine and adefovir. Hepatology. 2005; 41:1391–1398.
Article
19. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok AS. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology. 2006; 44:703–712.
Article
20. 권소영, 최원혁, 연종은 등. 라미부딘-아데포비어 sequential monotherapy에 내성을 보인 만성 B형간염 환자에서 라미부딘 병합치료의 항바이러스 효과와 내성 변이 발현에 관한 연구. 대한간학회 춘계학술대회 초록집. 2006; 12(suppl 3):S81.